HEPATOCELLULAR CARCINOMA

This early-stage trial tests a DNA vaccine for people with long-term hepatitis C infection. The vaccine is designed to teach the immune system to recognize and attack the virus, potentially lowering the risk of liver cancer. About 33 adults with active hepatitis C will receive th…

This study is for adults with advanced liver cancer. It compares two treatment combos: radioactive beads (Therasphere) followed by either immunotherapy (Atezolizumab + Bevacizumab) or targeted pills (Lenvatinib or Cabozantinib). The goal is to see which combo better delays cancer…

This early-phase trial tests a cancer vaccine (IMA970A) plus an immunotherapy drug (durvalumab) in 10 people with early-stage liver cancer who have already had standard treatments. The goal is to see if the combination is safe and can lower the chance of the cancer returning. Par…

This study looks at adults with liver cancer that was initially too advanced for surgery but later disappeared after drug treatment. Researchers want to see if having surgery after that response helps people live longer compared to just watching and waiting. About 729 participant…

This study tests a combination of two drugs, atezolizumab and bevacizumab, in people with liver cancer or lung cancer that has spread to the liver. The goal is to see how long the cancer stays under control. Researchers will collect blood and tumor samples to understand how the d…

This study tests whether adding radiation therapy to a standard liver cancer treatment (chemoembolization) can better control the cancer while patients wait for a liver transplant. About 40 adults with liver cancer who are already listed for a transplant will take part. The goal …

This study tests whether adding two drugs (camrelizumab and rivoceranib) to a standard procedure called TACE can help people with incurable liver cancer live longer without the disease getting worse. About 423 participants will receive either the combination or TACE alone. The go…

This study tests whether adding immunotherapy drugs (durvalumab with or without bevacizumab) to a standard procedure called TACE can help control liver cancer that has not spread outside the liver. About 724 adults with liver cancer that cannot be surgically removed are participa…

This study tests whether a combination of three drugs (durvalumab, bevacizumab, tremelimumab) plus a procedure called TACE can help control advanced liver or bile duct cancer. About 27 adults with these cancers will receive the treatment in 21-day cycles. The main goal is to see …

This study tests a new oil called T-ACE Oil in people with liver cancer that cannot be removed by surgery. The oil is injected into the liver to block the blood supply to tumors. The trial will check if the treatment is safe and helps control the cancer. About 82 adults will take…

This study tests whether lisinopril, a widely used blood pressure medication, can slow liver scarring in people with non-alcoholic fatty liver disease (NAFLD). The goal is to see if it reduces the risk of liver cancer. About 45 adults with advanced liver scarring are taking lisin…

This study tests whether giving the drug cemiplimab (alone or with another drug called fianlimab) before surgery can shrink tumors in people with lung, liver, or head/neck cancers. About 65 participants will receive the treatment and then have surgery. Researchers will check how …

This study tests a new drug (ABSK-011) combined with atezolizumab or standard care in about 118 people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination is safe and can shrink tumors. Participants must have a specific genetic mark…

This early-stage study tests a new cancer vaccine (p53MVA) combined with the immunotherapy drug pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The vaccine helps the immune system recognize and attack cancer cells, while pembrolizum…

This early-phase study tests whether giving focused radiation and two immunotherapy drugs before surgery can safely help treat liver cancer that can be removed. About 20 adults with resectable hepatocellular carcinoma will receive stereotactic body radiation therapy (SBRT) follow…

This study tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with radiation therapy can shrink tumors in people with advanced liver cancer or bile duct cancer. About 37 adults whose cancer cannot be removed by surgery or has spread will receive the tre…

This study is for people with advanced solid tumors (like lung, bladder, or skin cancer) that have stopped responding to standard immunotherapy drugs called PD-1/PD-L1 inhibitors. Researchers are testing a new combination of immune-boosting drugs to see if they can shrink tumors …

This study looks at a new type of electrode used in radiofrequency ablation, a treatment that uses heat to destroy small liver cancers (up to 3 cm). The goal is to see if this new device can better control tumor regrowth and reduce damage to nearby organs. About 76 adults with li…

This study tests a two-step treatment for liver cancer. First, tiny radioactive beads (TheraSphere) are injected into the liver to target tumors. Then, two immunotherapy drugs (durvalumab and tremelimumab) are given to boost the immune system. The goal is to see if this combinati…

This study tested two immune-boosting drugs, durvalumab and tremelimumab, given alone or together (sometimes with a third drug, bevacizumab) in 433 adults with advanced liver cancer. The goal was to see if these treatments are safe and can shrink or slow the cancer. Participants …

This early-phase trial tests a new drug called BI-1910, alone or with pembrolizumab, in people with advanced solid tumors (like lung or liver cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug s…

This early-phase study tests a new drug called AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment. The goal is to find the safest dose and see if it can shrink tumors in people with advanced cancers like melanoma, lung, and ovarian canc…

This study tests whether adding a new drug, casdozokitug, to two existing cancer drugs (toripalimab and bevacizumab) can better control advanced liver cancer. About 72 adults whose cancer cannot be removed by surgery or has spread will participate. The main goals are to check saf…

This study tests a combination of two drugs, pembrolizumab and bavituximab, in people with advanced liver cancer that cannot be treated with surgery or local therapies. The goal is to see if the combination shrinks tumors and improves survival. About 35 participants will receive …

This study tests whether the immunotherapy drug nivolumab can delay or prevent liver cancer from returning in patients who have already had surgery or ablation to remove their tumors. About 545 participants at high risk of recurrence will receive either nivolumab or a placebo. Th…

This study tests a daily pill called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. The drug works by blocking signals that help tumors grow and form blood vessel…

This study tests whether combining two drugs, lenvatinib and VIC-1911, can safely shrink tumors and slow cancer growth in people with advanced liver cancer. About 12 adults aged 18-75 with stage C liver cancer and good liver function are taking part. The goal is to see how well t…

This study tests whether adding a targeted chemotherapy infusion directly into the liver's blood supply (HAIC) to two immunotherapy drugs (camrelizumab and apatinib) helps people with advanced liver cancer that has invaded the portal vein live longer. About 214 participants who h…

This study tests whether adding the drug lenvatinib before and after a standard tumor-burning procedure (ablation) can prevent liver cancer from returning in patients at high risk of recurrence. About 32 adults with early-stage liver cancer and certain aggressive features will re…

This early-phase study tests whether adding a new drug called NP137 to the standard two-drug therapy (Atezolizumab and Bevacizumab) can help shrink tumors and extend life in people with advanced liver cancer that cannot be removed by surgery. About 43 adults with this type of liv…

This early-stage trial tests a new treatment called BOXR1030, which uses specially engineered immune cells to attack cancer cells that have a protein called GPC3. The study includes adults with advanced liver, lung, skin, or soft-tissue cancers that have not responded to other tr…

This phase 3 study tested two immunotherapy drugs (durvalumab and tremelimumab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. Over 1,300 participants received either the drug combination, durvalumab alone, or the standard drug soraf…

This study tests a new treatment called AZD5851 for adults with advanced or recurrent liver cancer. The treatment uses specially engineered immune cells (CAR-T cells) to target a protein called GPC3 found on cancer cells. The main goals are to check if the treatment is safe and t…

This study tests whether adding the drugs durvalumab (alone or with bevacizumab) after surgery or ablation can prevent liver cancer from returning in patients at high risk. About 900 adults who have had their liver cancer completely removed or destroyed are randomly assigned to r…

This early-stage trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in 120 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find safe doses and check for side effects, while also measur…

This study tests an experimental immunotherapy called AlloStim against standard treatments (Sorafenib, Lenvatinib, or FOLFOX4) in 150 Asian adults with advanced liver cancer. The main goal is to see if AlloStim helps people live longer. The study is currently suspended.

This study tests whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) works better than standard targeted therapy drugs (sorafenib or lenvatinib) for people with advanced liver cancer who haven't had prior treatment. About 732 participants will be enrolled …

This study tests a device that uses sound waves (histotripsy) to break apart liver tumors without needles or surgery. About 47 adults with liver cancer or tumors that spread to the liver will receive this treatment. The goal is to see if the device can safely and completely destr…

This study tests whether adding a new drug called tiragolumab to a standard two-drug combination (atezolizumab and bevacizumab) can help people with advanced liver cancer live longer or slow their cancer's growth. About 687 participants who have not had prior treatment for their …

This study tests a device that uses sound waves (histotripsy) to break apart liver tumors without cutting into the body. About 24 adults with liver cancer or tumors that spread to the liver will receive this treatment. The goal is to see if the device can safely and completely de…

This study tests whether a combination of two drugs, cabozantinib and atezolizumab, works better than the standard drug sorafenib for people with advanced liver cancer who have not had other cancer treatments. About 837 adults took part. The goal is to see if the new combo helps …

This study tests whether adding nofazinlimab to lenvatinib helps people with advanced liver cancer live longer. About 534 adults who have not had prior systemic treatment will receive either the combo or lenvatinib alone. The main goal is to see if the combination improves overal…

This study tests whether adding two drugs (atezolizumab and bevacizumab) to a standard liver cancer procedure called TACE helps people with untreated liver cancer live longer or delay cancer growth. About 342 participants will receive either the drug combo plus TACE or TACE alone…

This early-stage study aimed to test a drug made from black seed (NP-101) alongside standard radiation therapy for people with liver cancer that cannot be removed by surgery. The goal was to find the safest dose and see if it could help control the cancer. However, the study was …

This early-stage study tests whether giving immunotherapy drugs (nivolumab alone or with relatlimab) before and after surgery is safe and helps patients with liver cancer that can be removed. About 31 adults with resectable liver cancer will receive the drugs, then undergo surger…

This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) with or without a targeted therapy (lenvatinib) to a standard procedure called TACE can help people with liver cancer that cannot be surgically removed. About 760 participants will be randomly a…

This study tests a new way of giving the drug regorafenib to people with advanced liver cancer. Instead of starting at a high dose, the dose is slowly increased over the first two treatment cycles to find the highest dose each person can handle without severe side effects. The go…

This study tests whether adding a chemotherapy drug (doxorubicin) to the targeted therapy sorafenib can help people with advanced liver cancer whose disease got worse on sorafenib alone. About 30 adults with confirmed liver cancer and mild or no cirrhosis will receive the combina…

This study tests a combination of three drugs (durvalumab, tremelimumab, and lenvatinib) as the first treatment for people with advanced liver cancer that cannot be removed by surgery. About 114 participants will receive the drugs to see if they can slow cancer growth and improve…

This early-phase study tests an experimental drug called ABBV-400 in about 302 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The main goals are to check safety, side effects, and whether the drug shrinks tumors. Participants receive …

This study tests a treatment called Eye90 microspheres for people with liver cancer that cannot be removed by surgery. The tiny beads deliver radiation directly to tumors to shrink them. The trial involves 120 participants and measures how well the tumors respond and how safe the…

This study looks at whether using two contrast agents in MRI scans can help doctors find and identify both non-cancerous and cancerous liver spots more accurately. About 100 adults with recent abdominal MRIs will take part. The goal is to improve diagnosis without any direct trea…

This study is testing a new blood test called Oncoguard™ Liver to see how well it finds liver cancer early in people who are at high risk, such as those with cirrhosis or hepatitis B. About 3,000 adults will take part, and the test's accuracy will be compared to standard ultrasou…

This study uses CT scans and artificial intelligence (AI) to find liver cancer earlier. Researchers will analyze images from 10,000 patients with confirmed liver tumors. The AI helps outline tumors, and doctors check the results to improve accuracy. The goal is to create a better…

This study tests whether simvastatin, a widely used cholesterol medication, can stop liver cancer from developing in people with liver cirrhosis. About 52 adults with confirmed cirrhosis will take simvastatin, and researchers will measure changes in blood markers linked to liver …

This early-phase trial studies the safety and best dose of radiation therapy for people with liver cancer (hepatocellular carcinoma, cholangiocarcinoma, or cancer that spread to the liver) who also have liver damage from cirrhosis, chemotherapy, or surgery. About 36 participants …

This study follows 1000 adults with liver cancer (hepatocellular carcinoma) who receive a liver transplant. Researchers will track how long patients stay cancer-free and how long they live overall. The goal is to learn what factors predict cancer recurrence after transplant.

This study tests whether a special pressure-enabled catheter delivers radioactive tracer more precisely to liver tumors than a standard catheter. Twenty adults with liver cancer who are scheduled for radioembolization will receive both catheters during the mapping procedure. The …

This study is for adults with liver cancer who have had or plan to have immunotherapy. Researchers will collect blood, urine, stool, and tissue samples, along with medical records, to build a large database. The goal is to learn more about how liver cancer develops and responds t…

This early-phase study tests a new imaging tracer called 68Ga-FAPI-46 in 26 people with various cancers. The tracer targets cells around tumors, helping PET scans show where cancer is located. Researchers want to see how well the tracer works and compare it to standard imaging. T…

This study follows over 2,700 patients with bladder, lung, or liver cancer who are receiving the drug atezolizumab as part of their normal care. Researchers are tracking how long patients live and how well the drug controls their cancer outside of a controlled trial setting. The …

This study tests a decision aid tool that helps VA medical centers choose the best strategies to improve liver cancer screening in patients with cirrhosis. About 8,020 veterans and VA staff will take part. The goal is to see if the tool increases screening rates and catches cance…

This study tests whether an automatic reminder in the medical record helps doctors order liver ultrasounds for patients with cirrhosis. About 1,300 adults with cirrhosis who haven't had recent imaging will be included. The goal is to see if the reminder increases screening rates …

This study tests whether sending mailed invitations and assigning patient navigators can increase the number of people who attend regular liver cancer (HCC) ultrasound screenings. The study includes 652 adults with liver cirrhosis or chronic hepatitis B who are at high risk for l…